Qui Tam Basics

Federal and State False Claims Act


Facts You Should Know About Qui Tam



Tax Whistleblower Laws



Securities and Commodities Whistleblower Laws



Articles


Whistleblower Stories



Resources


Contact Us About a Potential Case



Home


Qui tam Whistleblowers
This site provides news and information about the False Claims Act qui tam whistleblower law, the Tax Whistleblower law and the Securities and Commodities Whistleblower law. On this site you can learn the basics of each law and the process of bringing a case as well as read about the latest developments.

Getnick & Getnick LLP is a Manhattan-based law firm dedicated to business integrity and anti-fraud cases. Our whistleblower cases have resulted in recoveries of over a billion dollars for U.S. taxpayers.
Daily Blog Search


Advanced Blog Search

Monthly Archives
Most recent entries
Syndicate

Tuesday, November 08, 2011

SDNY Judge Skeptical of Corporate Integrity Agreements

As Citigroup prepares to settle allegations of its most recent securities fraud violations, the district judge tasked with evaluating the settlement has approached the SEC’s handling of such cases with skepticism.  Judge Rakoff has questioned the effectiveness of Citigroup’s corporate integrity agreement, under which the company has agreed not engage in fraudulent activity in the future.  Although many companies sign corporate integrity agreements, a significant portion get caught for similar activity shortly thereafter.  The New York Times recently identified nineteen repeat offenders, all high-profile Wall Street firms.  Despite the fact that many companies violate their integrity agreements--including financial giants like Citigroup, Goldman Sachs, Morgan Stanley, JP Morgan Chase, and Bank of America--the SEC told Judge Rakoff that it has not brought any contempt proceedings against violators in the last ten years.  Several critics, including U.S. Senator Carl Levin, have questioned the ability of such unenforced agreements to serve as an effective deterrent of future fraud.

Read the entire article, “Promises Made, and Remade, by Firms in S.E.C. Fraud Cases"

Posted by eithurburn on 11/08 at 06:13 PM
Permalink

Concerns Surrounding Anemia Drugs Grow

A new book has been published that reiterates many of the allegations of recent lawsuits surrounding the marketing of anemia drugs Aranesp, Procrit, and Epogen, which are all manufactured by Amgen.  One of the drugs, Procrit, is marketed and sold by Johnson & Johnson.  According to recent allegations and FDA findings, these drugs, which were increasingly prescribed to purportedly improve the quality of life of patients with serious diseases such as cancer and AIDS, may actually increase cancer growth rates and lead to significant heart problems.  The FDA recently concluded that there was no dosage that was able to eliminate the risks posed by the drug and have counseled physicians to confine use only to patients who suffer from anemia, the drug’s original intended purpose.

Amgen has reached a settlement in principle in relation to these allegations and is expected to pay $780 million.

Read the entire article, “Medicare’s Blood Drugs"

Posted by eithurburn on 11/08 at 06:11 PM
Permalink

Another Bullet-Proof Vest Manufacturer Settles

Point Blank Solutions Inc. has agreed to pay $1 million to resolve allegations that it sold defective body armor to government law enforcement agencies.  Point Blank continued to manufacture bullet-proof vests with Zylon, even though they allegedly knew the material degraded quickly, causing it to lose its bullet-proof properties.

Point Blank is one of several corporations investigated by the Department of Justice.  Several suits are still pending.

Read the entire article, “Bullet proof vest maker pays $1 million penalty for selling defective products"
Read our earlier post on Zylon-related litigation, “False Claims Act Case against Bulletproof Vest Manufacturer Proceeds"

Posted by eithurburn on 11/08 at 06:08 PM
Permalink

Monday, November 07, 2011

Botox Maker Receives Civil Investigative Demand

According to the company’s recent regulatory filings, Allergan, the maker of Botox, received a Civil Investigative Demand in September from the Massachusetts Attorney General’s office.  The civil investigative demand supposedly relates to its eye-care group.

Read the entire article, “Allergan Says Massachusetts AG Wants Documents on Group"

Posted by eithurburn on 11/07 at 06:07 PM
Permalink

Friday, November 04, 2011

GSK to Pay $3 Billion

Glaxo Smith Kline has agreed to pay $3 billion to resolve multiple claims against it.  Among the allegations resolved by the settlement are its development and marketing of Avandia, a diabetes drug that has been linked to heart risks, improper marketing of Paxil and Wellbutrin between 1997 and 2004, and abusive Medicaid billing practices.

In 2010, GSK paid $2.4 billion to resolve several unrelated cases, $750 million of which resulted from a suit brought by Getnick & Getnick LLP regarding quality control deficiencies at GSK’s manufacturing plant in Cidra, Puerto Rico.

Read the entire article, “Glaxo to Pay U.S. $3 Billion to Settle"

Posted by eithurburn on 11/04 at 06:04 PM
Permalink
Page 3 of 4 pages « First  <  1 2 3 4 >
Printer Friendly Printer Friendly Page
Disclaimer
This Site supported by Getnick & Getnick LLP Copyright © 2006

Designed, Developed and Maintained By Interactive Media Associates, Inc.